New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
ApexOnco Front Page
Recent articles
The project has priority review, but deaths could raise eyebrows.
A common mutation comes into play for PRMT5 inhibition.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Tolerability could decide first-line therapy in EGFRm disease.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
